No ROS1 rearrangements were identified in our study, which is in accordance with findings from some previous studies, identifying ROS1 rearrangements and fusions that seldom coincide with modifications in EGFR, KRAS, ALK or other actionable oncogenes in NSCLC [55], although there are studies with contrasting findings (e.g., [56]) indicating rare co-mutations with EGFR (exon 19 deletions, exon 20 insertions, L858R) and extremely rare BRAF, ALK and KRAS co-mutations [55]. Here, BRAF is linked to non-small cell lung carcinoma.